Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

735.20
+0.39000.05%
Post-market: 737.802.60+0.35%17:29 EDT
Volume:613.94K
Turnover:451.26M
Market Cap:75.69B
PE:18.18
High:742.50
Open:740.50
Low:729.20
Close:734.81
52wk High:859.34
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.69
T/O Rate:0.62%
Dividend:3.64
Dividend Rate:0.50%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.39
PE(LYR):17.72

Loading ...

Movement Alert|Regeneron Pharmaceuticals Falls 3.52% in Regular Trading, Trading at $760.15

Market Focus
·
Sep 28

Kodiak Sciences Rises After Eye-Disease Drugs Meet Trial Goals

Reuters
·
Sep 28

Regeneron (REGN) Receives a Hold from Bernstein

TIPRANKS
·
Sep 26

Analysts Are Bullish on Top Healthcare Stocks: Agilent (A), Regeneron (REGN)

TIPRANKS
·
Sep 26

Regeneron Pharmaceuticals Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 26

US FDA Approves Mirum's Drug for Rare Bone Disorder

Reuters
·
Sep 26

Regeneron Steps Into Obesity Drug Race With New Phase 1 Study

TIPRANKS
·
Sep 26

Regeneron to Report Q3 Results, Host Conference Call and Webcast

Reuters
·
Sep 25

Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026

GlobeNewswire
·
Sep 25

Regeneron Approaching Incremental Catalysts Like Upcoming Olatorepatide Data Readout, RBC Says

MT Newswires Live
·
Sep 24

Pharmaceutical Stocks Jump. Moderna, Eli Lilly up over 3%; Novavax, Pfizer up Around 2%; Merck, Novo Nordisk up over 1%

Tiger Newspress
·
Sep 24

Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Sep 22

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 15

Regeneron and Sanofi Complete Key Dupilumab Itch Study, Expanding Dermatology Upside

TIPRANKS
·
Sep 12

S&P 500 Futures up in Premarket Trading; South Bow, Oracle Lead

Dow Jones
·
Sep 11

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Sep 11

Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says

MT Newswires Live
·
Sep 10

Sanofi, Regeneron Could Extend Dupixent Patent

Dow Jones
·
Sep 09

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $920 From $800, Keeps Outperform Rating

MT Newswires Live
·
Sep 09

Regeneron Pharmaceuticals, Inc. : Bmo Raises Target Price to $920 from $800

THOMSON REUTERS
·
Sep 09